A cautionary note on recall vaccination in ex-COVID-19 subjects

Riccardo Levi, MSc*[1,2], Elena Azzolini, MD PhD*[1, 2], Chiara Pozzi, PhD*[2], Leonardo Ubaldi, MSc[1]*, Michele Lagioia[2], MD, Alberto Mantovani, MD[1, 2, 3] and Maria Rescigno, PhD[1, 2, #]

[1]Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.
[2]IRCSS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
[3]The William Harvey Research Institute, Queen Mary University of London, London, UK

*These authors contributed equally

[#]Corresponding author:
E-mail: maria.rescigno@hunimed.eu
Humanitas University
Via Rita Levi Montalcini, 4
20090 Pieve Emanuele (Mi) Italy

Abstract

Currently approved COVID-19 vaccines based on mRNA or adenovirus require a first jab followed by recall immunization. There is no indication as to whether individuals who have recovered from COVID-19 should be vaccinated, and if so, if they should receive one or two vaccine doses. Here, we tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2) in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID). Post-vaccine antibodies in ExCOVID individuals increase exponentially within 7-15 days after the first dose compared to naïve subjects ($p<0.0001$). We developed a multivariate Linear Regression (LR) model with l2 regularization to predict the IgG response for SARS-COV-2 vaccine. We found that the antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR. Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects. On the contrary, a second dose might switch-off the immune response due to antigen exhaustion, which occurs in response to several viruses or drive the development of low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement (ADE) reaction when re-exposed to the virus. These results question whether a second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring antibody response longevity.

Introduction

Currently approved COVID-19 vaccines based on mRNA [1-3] or adenovirus [4] require a first jab followed by recall immunization. The impact of previous exposure to SARS-CoV-2 on immune response elicited the vaccines has not been assessed.

Methods

We tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2)[1] in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID) (Table 1), as part of an observational study (clinicaltrial.gov NCT04387929) conducted at Istituto Clinico Humanitas in which healthcare professionals were followed for serology and for any occurring COVID-19 related symptoms every three months[5]. We recorded the antibody response to Spike 1/2 with a quantitative test (Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy) which allowed us to evaluate even large amounts of plasma IgG. To predict the IgG response for SARS-COV-2 vaccine, a multivariate Linear Regression (LR) model with l2 regularization (also known as Ridge Regression) was developed. Numerical variables were standardized (z-score algorithm) and the target variable was log transformed due to right asymmetry of the distribution. The subjects without the serological analysis before vaccination were excluded from this analysis (n=11). The final number of subjects analyzed in LR was 113.

Results

As shown in Fig.1A-B ExCOVID individuals had a much higher antibody response after the first dose of vaccine than naïve subjects ($p<0.0001$), regardless of when they developed the COVID-19. They displayed an exponential increase of anti-Spike 1/2 antibody response within 7-15 days after the first dose of vaccine. The pre-vaccine antibody amount of the ExCOVID population was on average 44.+/-37.7 while that after the vaccine was 1055.7+/-1004.2 ($p<0.0001$) (Table 1), with higher levels in symptomatic ExCOVID (Fig. 1C, $p=0.028$).

We investigated the relationship between the amount of IgG after vaccination with COVID-19, sex, age and symptoms related to disease. The final LR shows a good prediction of the target variable ($R^2=0.88$, F-statistic = 39.18, p-value<0.001) and the most significant features were history of COVID-19 (1.48, 95% CI 1.07-1.93), the value of IgG before vaccination (0.87, 95% CI 0.59-1.13), the difference between the date of vaccination and the date of serology post-vax (0.87, 95% CI 0.65-1.03), and age (-0.13, 95% CI -0.24 - -0.001) as well as COVID-19 related symptoms: gastrointestinal disorders (0.59, 95% CI 0.16-0.97), anosmia/dysgeusia (0.50, 95% CI 0.14-0.87),

tachycardia (0.26, 95% CI 0.02-0.60) and sore throat (-0.35, 95% CI -0.53 - -0.11) (Fig. 1D, Suppl. Table1).

Discussion

The antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR, while sore throat was negatively correlated because 45% non-COVID individuals reported it. Young subjects had a higher antibody response. We previously observed that anosmia/dysgeusia was associated with an increase of antibodies over time, independently of vaccination (Levi et al. submitted). Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects and poses caution for a second dose: over stimulation with high amount of antigens could switch-off the immune response due to antigen exhaustion, which occurs in response to several viruses (reviewed in[6]). Alternatively, overactivation of the immune response may drive the development of low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement (ADE) reaction when re-exposed to the virus (reviewed in[7]). These results question whether a second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring antibody response longevity. At a time of vaccine scarcity, these findings may have public health implications.

References

1. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med.* 2020;383(25):2439-2450.
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.

3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2020.

4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397(10269):99-111.

5. Sandri MT, Azzolini E, Torri V, et al. SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *medRxiv.* 2020:2020.2005.2024.20111245.

6. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. *Immunology*. 2010;129(4):474-481.

7. Flanagan KL, Best E, Crawford NW, et al. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. *Front Immunol.* 2020;11:579250.

A

		Serology pre VAX							
		counts	**%**	**min**	**max**	**mean**	**std**	**TEST**	***p***
COVID-19	**NO (Healthy)**	67	59.29	3	7.66	3.35	1.02	MW	5E-12
	YES (ExCOVID)	46	40.71	3	140	44.58	37.72		
GENDER	**F**	63	55.75	3	132	18.86	28.46	MW	0.295
	M	50	44.25	3	140	21.74	34.99		
Age_class	**21-30**	24	21.24	3	140	29.25	38.82	MW	0.027
	31-40	37	32.74	3	132	16.56	28.14	MW	0.086
	41-50	31	27.43	3	81.7	14.76	22.91	MW	0.074
	51-60	13	11.5	3	123	25.73	42.37	KS	0.146
	60+	8	7.08	3	78.1	21.12	29.81	KS	0.986

B

			Serology post VAX							
			counts	**%**	**min**	**max**	**mean**	**std**	**TEST**	***p***
	COVID-19	**NO (Healthy)**	67	54.03	3	104	13.29	19.73	MW	3E-19
		YES (ExCOVID)	57	45.97	3	4000	1055.7	1004.2		
	GENDER	**F**	71	57.26	3	3800	466.97	875.9	MW	0.455
		M	53	42.74	3	4000	526.62	833.75		
	Age_class	**21-30**	30	24.19	3	4000	601.13	901.65	MW	0.015
		31-40	39	31.45	3	3800	553.52	1046.9	MW	0.115
		41-50	33	26.61	3	2320	351.12	644.59	MW	0.234
		51-60	14	11.29	3	2240	437.95	740.98	KS	0.986
		60+	8	6.45	3	1690	465.76	664.78	KS	0.696
	CLASS SYMPTOMS (for ExCOVID)	**a/paucisymptomatic**	15	26.32	3	1800	507.73	598.39	KS	0.029
		symptomatic	42	73.68	10.7	4000	1251.4	1051.6		
ExCOVID	**Fever**	**0**	30	52.63	3	3800	865.65	942.76	MW	0.034
		1	27	47.37	10.7	4000	1266.9	1045.2		
	Low-grade Fever	**0**	44	77.19	3	4000	954.8	1060.1	KS	0.016
		1	13	22.81	27	2630	1397.2	717.47		
	Headache	**0**	31	54.39	3	2520	825.63	734.51	MW	0.038
		1	26	45.61	27	4000	1330	1211.4		
	Cough	**0**	40	70.18	3	3800	921.12	959.53	KS	0.176
		1	17	29.82	8.18	4000	1372.4	1064.5		
	Sore throath	**0**	31	54.39	3	3330	1040.9	857.41	MW	0.365
		1	26	45.61	8.18	4000	1073.4	1173		
	Muscle pain	**0**	27	47.37	3	4000	864.43	1100.9	MW	0.013
		1	30	52.63	10.7	3330	1227.9	892.15		
	Asthenia	**0**	25	43.86	3	2520	717.64	784.71	MW	0.008
		1	32	56.14	10.7	4000	1319.8	1086.6		
	Anosmia/dysgeusia	**0**	29	50.88	3	4000	824.28	1044.4	MW	0.009
		1	28	49.12	27	3800	1295.4	918.26		
	Gastrointestinal disorders	**0**	33	57.89	8.18	2520	902.12	753.36	MW	0.212
		1	24	42.11	3	4000	1266.9	1259		
	Conjunctivitis	**0**	49	85.96	3	4000	1018.2	984.56	KS	0.896
		1	8	14.04	27	3330	1285.8	1161.6		

	Dyspnea	**0**	41	71.93	3	4000	952.52	1017.5	KS	0.179
		1	16	28.07	27	3330	1320.1	948.76		
	Chest pain	**0**	42	73.68	3	4000	989.3	988.56	KS	0.819
		1	15	26.32	27	3330	1241.6	1058.9		
	Tachycardia	**0**	47	82.46	3	3800	982.11	870.62	KS	0.395
		1	10	17.54	27	4000	1401.6	1496.3		
	Pneumonia	**0**	50	87.72	3	4000	1013.9	1036.5	KS	0.218
		1	7	12.28	27	2240	1354.3	720.25		
Healthy	**Fever**	**0**	63	94.03	3	104	13.45	20.13	KS	0.995
		1	4	5.97	3	30.7	10.74	13.4		
	Low-grade Fever	**0**	62	92.54	3	104	14.04	20.33	KS	0.559
		1	5	7.46	3	6.26	3.9	1.42		
	Headache	**0**	42	62.69	3	104	12.68	20.73	MW	0.438
		1	25	37.31	3	60.5	14.3	18.28		
	Cough	**0**	51	76.12	3	104	12.52	20.12	KS	0.126
		1	16	23.88	3	63.8	15.72	18.85		
	Sore throath	**0**	37	55.22	3	60.5	11.02	15.69	MW	0.256
		1	30	44.78	3	104	16.08	23.78		
	Muscle pain	**0**	58	86.57	3	104	12.54	19.49	KS	0.724
		1	9	13.43	3	55.9	18.11	21.79		
	Asthenia	**0**	56	83.58	3	104	12.23	19.47	KS	0.419
		1	11	16.42	3	49.7	18.68	21.11		
	Anosmia/dysgeusia	**0**	66	98.51	3	104	13.4	19.86	KS	0.687
		1	1	1.49	6.13	6.13	6.13			
	Gastrointestinal disorders	**0**	58	86.57	3	104	13.3	20.1	KS	0.656
		1	9	13.43	3	55.9	13.2	18.24		
	Conjunctivitis	**0**	60	89.55	3	63.8	11.5	16.12	KS	0.419
		1	7	10.45	3	104	28.62	37.68		
	Dyspnea	**0**	64	95.52	3	104	13.75	20.07	KS	0.399
		1	3	4.48	3	4.5	3.5	0.87		
	Chest pain	**0**	63	94.03	3	104	13.92	20.19	KS	0.205
		1	4	5.97	3	4.4	3.35	0.7		
	Tachycardia	**0**	62	92.54	3	104	14.07	20.32	KS	0.195
		1	5	7.46	3	4.57	3.61	0.84		
	Pneumonia	**0**	67	100	3	104	13.29	19.73	na	na
		1	0	0	0	0	0	0		

C

		counts	**%**	**min**	**max**	**mean**	**std**	**TEST**	***p***
Days between VAX and serology post VAX	**Healthy**	67	54.03	4.8	16.9	8.9	2.91	MW	3E-08
	ExCOVID	57	45.97	4.89	20.4	13.81	4.91		

Table 1. A.B. Demographic distribution of anti-Spike 1/2 IgG plasma levels. C. Days between vaccination and serology post vaccination. *P* values determined using two-tailed unpaired Mann–Whitney test (MW) or two-tailed unpaired Kolmogorov-Smirnov test (KS). NA: not applicable.



Figure 1: ExCOVID subjects increase exponentially anti-Spike 1/2 IgG levels after the first dose of vaccine. A, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=57) measured after the first dose of vaccine. B, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=46) measured before and after the first dose of vaccine. C, anti-Spike 1/2 IgG plasma levels in asymptomatic / paucisymptomatic (n=15) and in symptomatic (n=42) ExCOVID individuals measured after the first dose of vaccine. D, Multivariate linear regression coefficients for the most significant variables (p<0.05). Dot points represent the mean values and the lines the 95% CI.

The box plots (A, C) show the interquartile range, the horizontal lines show the median values and the whiskers indicate the minimum-to-maximum range. *P* values were determined using two-tailed unpaired Mann–Whitney test (A) or two-tailed Wilcoxon matched-pairs signed rank test (B) or two-tailed unpaired Kolmogorov-Smirnov test (C).